Medical Oncologist
CION Cancer Clinics
Molecular profiling in liver cancer: is it useful yet? | CION Cancer Clinics
For bile duct cancer inside the liver, molecular profiling is useful now: some tumours carry gene changes with a matching targeted medicine. For hepatocellular carcinoma, the common kind, it rarely changes the first treatment today. This page explains what the test looks for, how it is done, who it does not suit, and what to ask before you pay for it. At CION Cancer Clinics, a multidisciplinary tumour board weighs your liver function and your scans before recommending any treatment.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed October 2026, next review due October 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- Is molecular profiling useful in liver cancer yet?
- Why the answer differs for HCC and bile duct cancer
- Which gene changes matter in liver and bile duct cancer?
- How does molecular testing actually happen?
- What families expect from a gene test, and what is true
- Who this does not suit, and what this page cannot tell you
- Common questions about molecular profiling in liver cancer
The short answer
Is molecular profiling useful in liver cancer yet?
It depends on which liver cancer you have. For bile duct cancer inside the liver (intrahepatic cholangiocarcinoma), yes: testing the tumour's DNA is recommended, because some changes have a matching targeted medicine. For hepatocellular carcinoma (HCC), the common kind, it rarely changes treatment today.
What molecular profiling means
Molecular profiling is a laboratory test that reads the genes inside a tumour sample, looking for changes that drive the cancer. It is often done by next-generation sequencing (NGS), which checks many genes at once from one sample. It looks at the tumour, not at what you inherited.
Which reader this page is for
This page is about cancer that started in the liver. If the cancer spread to the liver from the bowel, the testing follows the bowel cancer. See colon cancer spread to the liver. Gallbladder cancer has its own hub at gallbladder cancer.
A gene report is a guide to treatment options. It is not a forecast of how anyone will do.Side by side
Why the answer differs for HCC and bile duct cancer
Hepatocellular carcinoma
Intrahepatic cholangiocarcinoma
Usually diagnosed from a scan, often without a biopsy
Needs a biopsy, which also gives tissue to test
No gene change currently picks the first medicine
Several changes have a matching targeted medicine
Treatment chosen on stage, liver function and fitness
Treatment chosen on stage, fitness and the gene report
Testing mainly useful for a trial or an unusual tumour
Testing advised for advanced or returning disease
Not sure whether this applies to you?
Ask an oncologistWhat the test looks for
Which gene changes matter in liver and bile duct cancer?
Most of these are found in bile duct cancer. Finding one opens a conversation. It does not mean a medicine is ready for you.
FGFR2 fusions
Two genes joined together in a way that drives growth. Found in a minority of intrahepatic cholangiocarcinomas. Medicines such as pemigatinib target it. Read FGFR2 fusions in bile duct cancer.
IDH1 mutations
A change in a gene that controls the cell's chemistry. Ivosidenib was developed for it. It is tested for on the same panel as FGFR2, so one sample answers both questions. See IDH1 mutations in bile duct cancer.
Rarer findings
A few tumours carry changes seen in other cancers, where a medicine already exists. They are uncommon, which is why a broad panel is usually chosen over testing one gene at a time.
- HER2 changes
- BRAF V600E
- NTRK fusions
- MSI-high, which can favour immunotherapy
In HCC
HCC often carries changes in genes such as TERT, CTNNB1 and TP53. None of these yet has a medicine that targets it. Researchers are studying whether they predict who responds to immunotherapy.
From biopsy to plan
How does molecular testing actually happen?
Enough tissue is kept
When a bile duct cancer is biopsied, the team asks the pathologist to keep enough tissue for gene testing. A small biopsy may run out after the diagnosis is made.
The sample goes to a specialist laboratory
The stored tissue block is sent to a laboratory that does NGS. CION arranges this through diagnostic partner laboratories. You do not need a new procedure if the old block has enough tumour in it.
Blood as a backup
If there is too little tissue, a blood test called a liquid biopsy can look for some changes. It can miss fusions, so a negative blood result is not the final word.
The tumour board decides
The report is reviewed with your scans and liver function. The board asks whether a matching medicine exists, whether it suits your liver, and whether it can be obtained in India.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Commonly believed
What families expect from a gene test, and what is true
"Every liver cancer should have a full gene panel."
For bile duct cancer, testing is advised. For most HCC, the result would not change the first treatment, and the money may be better kept for the treatment itself. Ask what a result would change before agreeing.
"If a change is found, the medicine will work."
A match raises the chance of a response. It does not settle it. Some people respond well, some briefly, and some not at all, and the cancer can later find a way around the medicine.
"No change found means nothing more can be done."
Most people with liver cancer are treated without a targeted gene match. Immunotherapy, chemotherapy, procedures and good symptom care still apply. A negative report simply means the plan is built on the standard options for your stage and liver.
"A gene change in the tumour will pass to my children."
Tumour changes arose in that tumour during life and are not inherited. A separate blood test is used if an inherited fault is ever suspected.
Being straight with you
Who this does not suit, and what this page cannot tell you
Testing rarely helps someone with HCC planned for surgery, ablation, TACE or transplant assessment, because those choices rest on the scan and the liver. It also helps little when the liver is failing badly, since few targeted medicines are safe then. Some matched medicines are not approved in India, or are reachable only through import, a trial or a named-patient programme, and the position changes. Your oncologist checks at the time.
It cannot read your report for you
Gene reports list many changes, and most do not matter for treatment. The same gene name can mean very different things depending on the exact change. Bring your report to an oncologist instead of searching each line online.
It cannot promise a trial
Some findings make a person eligible for research studies. This page is here to inform, not to recruit. The targeted therapy for bile duct cancer page explains the medicines themselves.
Not sure whether your tumour has been tested? Ask for the pathology and NGS reports and bring them to a consultation.Questions we are asked
Common questions about molecular profiling in liver cancer
Is NGS testing needed for hepatocellular carcinoma?
Usually not for choosing the first treatment. HCC is treated according to its stage, how well the liver works and how fit you are. Testing may be suggested for an unusual tumour, a mixed tumour, or when a trial is being considered. Ask what the result would change.
Why is testing advised for bile duct cancer?
Because a meaningful share of intrahepatic cholangiocarcinomas carry a change with a matching targeted medicine, such as an FGFR2 fusion or an IDH1 mutation. Knowing early lets the team plan the next step before it is needed.
What about a mixed HCC and bile duct tumour?
A combined tumour has features of both. Testing is often worth discussing because the bile duct part may carry a targetable change. Read about combined hepatocellular-cholangiocarcinoma.
Do I need another biopsy for the test?
Often not. The tissue block from your first biopsy or operation is usually stored and can be sent. If it holds too little tumour, the choice is a blood test or a repeat biopsy, and your team will explain which makes more sense for you.
How long do the results take?
It varies by laboratory and by how quickly the tissue block can be retrieved. Ask the laboratory for its expected turnaround when the sample is sent. Treatment does not always wait; your team may start a standard plan and adjust it when the report arrives.
How much does molecular profiling cost?
It is quoted separately and varies by laboratory and panel size. Insurance and government schemes may not cover it, and the rules change. Ask for a written, itemised estimate, and check with your insurer before the sample is sent.
Are the matched medicines available in India?
Some are, some are not approved here, and some can be reached only through import or a trial. Availability and price change. Your oncologist will check the current position for the specific medicine before building a plan around it.
Can CION arrange molecular testing?
Yes. CION oncologists decide whether testing is worthwhile, arrange it through diagnostic partner laboratories and review the report at the tumour board. If you were tested elsewhere, bring the report and it will be read with your scans.
Your Specialists
Meet CION's liver cancer specialists. Bring your scan reports and liver blood tests.
Our medical and surgical oncologists plan liver cancer care together, weighing the tumour and how well your liver works before choosing surgery, a liver-directed procedure or medicines.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- American Cancer Society — Bile Duct Cancer Targeted Therapy
- National Cancer Institute — Bile Duct Cancer Treatment
- American Cancer Society — Targeted Drug Therapy for Liver Cancer
- National Cancer Institute — Targeted Therapy for Cancer
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Why every biliary cancer should be molecularly testedThe bile duct case, in more detailLiquid biopsy and circulating tumour DNAThe blood-test backup when tissue runs outFGFR2 fusions in bile duct cancerThe most common targetable findingTargeted therapy for bile duct cancerHow the matched medicines work
Talk to us
Should your tumour be tested?
Share your pathology report and scans, and an oncologist will tell you plainly whether gene testing would change the plan. One helpline serves every CION centre.